• Co-Diagnostics’ reconvened annual shareholder meeting on October 14, 2026, lacked a quorum; none of the proposals received approval.
• Earlier sessions on September 3, September 24 and September 30, 2026, also failed to achieve a quorum.
• The company ended the meeting without another adjournment. It intends to seek approval of the proposals at a special shareholder meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-047242), on October 15, 2026, and is solely responsible for the information contained therein.